Kwon Y et al. |
Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report. |
2016 |
Chest |
pmid:27055712
|
Martin M et al. |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. |
2016 |
Ann. Oncol. |
pmid:27052654
|
Coiffier B et al. |
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. |
2016 |
Br. J. Haematol. |
pmid:27010483
|
Frenel JS et al. |
[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. |
2016 |
Bull Cancer |
pmid:26992855
|
Lanshoeft C et al. |
Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. |
2016 |
Rapid Commun. Mass Spectrom. |
pmid:26969923
|
Venkatesan P |
Trastuzumab emtansine for HER2-positive breast cancer. |
2016 |
Lancet Oncol. |
pmid:27866859
|
Sibaud V et al. |
T-DM1 extravasation: first description. |
2016 |
J Eur Acad Dermatol Venereol |
pmid:25879278
|
Li JY et al. |
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. |
2016 |
Cancer Cell |
pmid:26766593
|
Catcott KC et al. |
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. |
2016 |
MAbs |
pmid:26752675
|
Yan H et al. |
Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. |
2016 |
Mol. Cancer Ther. |
pmid:26712117
|
|
Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. |
2016 |
Cancer Discov |
pmid:26701087
|
|
T-DM1 Extends Survival in HER2+ Breast Cancer. |
2016 |
Cancer Discov |
pmid:26676162
|
Kan S et al. |
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. |
2015 |
BMC Cancer |
pmid:26475267
|
Hong EE et al. |
Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. |
2015 |
Mol. Pharm. |
pmid:25856201
|
Widdison W et al. |
Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. |
2015 |
Mol. Pharm. |
pmid:25826705
|
Guerin M et al. |
[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. |
2015 |
Bull Cancer |
pmid:25790739
|
Nguyen-Ngoc T and Raymond E |
Reinvention of chemotherapy: drug conjugates and nanoparticles. |
2015 |
Curr Opin Oncol |
pmid:25783982
|
Mustacchi G et al. |
HER2-positive metastatic breast cancer: a changing scenario. |
2015 |
Crit. Rev. Oncol. Hematol. |
pmid:25748080
|
Singh JC and Lichtman SM |
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. |
2015 |
Drugs Aging |
pmid:26645293
|
Hamblett KJ et al. |
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. |
2015 |
Cancer Res. |
pmid:26631267
|